It is well-known fact that funDr markers are used to investigate whether malignant tumors have been operated sufficiently and radically and to rectify or falsify a renewed growth of the tumor. After CA 19-9 had proved to be a highly sensitive marker in the differential diagnosis between pancreatic carcinoma and chronic pancreatitis as well as in the perioperative follow-up, it was the aim of the present study to conioare the monoganglioside antigen CA19--9 with CEA with regard to its sensitivity (SE) and specificity (SP) in diagnosing the different stages of colorectal and gastric carcinoma and in detecting recidivation during the aftercare treatment. Pre-and postoperatively CA 19-9 and CEA &re estigated in 82 pts. with colorectal carcinoma (CRC) and in 57 pts. with gastric carcinoma (GC) radio~ologically. Results:
Tumor stages (GC) CA 19-9 I II III IV I 6-37 U/ml 15 10 4 7 22 >37 U/ml I 4 5 11 I ~A 9 3 ng/ml 11 8 3 5 16 > 3 ng/ml 5 6 6 13 7
Tumor stages (CRC)  II  III  IV  23  7  15  I  2  11   14  3  8  10  6 18 The coaparison depending on stages between the markers CEA and CA 19-9 shows an increased sensitivity of the CBA in all stages of GC and CRC. In our cases of 66 pts. with GC and 165 pts.with ~ who were all surgically treated, CA 19-9 and CEA were estimated at the same time in the outpatients' department. From the exact clinical evalulation of CA 19-9 and CFA estimation in these patients the following conclusion could be established: CEA is more sensitive than CA 19-9, but CA 19-9 is more specific. The sepcificity, sensitivity, and total accuracy increases, if both markers are used. The stlmulatlon of monocytes is followed by a respiratory burst which is characterized by a non mitochondrial oxygen consumption. There is a consecutive production of activated oxygen species, which generate chemiluminescence after relaxation and photon emission. The aim of thls study was to evaluate the C3 activatlon capacity (At) in controls and coiorectal cancer patients of different stages by monocyte medlated chemiluminescence. Rnthods: 48 patients (iz+ controls and 3L colorectal cancer) were examined for the C3 activating capaclty. Blood was drawn from the cubital vein and separated serum was frozen at -70%. To evaduate the C3 AC each serum sample was divided in two portions, one remaining untreated (acand the other being inactivated (inactlve) at 56 ~ for 30 min. tLix~l isolated ....... i ..... 11s includlng ..... yt .... d lymphoeytes of healthy donors were incubated in 300 pl DMEM and i0 NI (2 mg/ml) lumi nol. 35 I~i of either active or inactlve serum was added and CL reaction was started by adding I0 pl zymosan (5mg/ml). 20 minute integral relation of the dynamic CL-measurement of activated and inactivated serum was named C3b-index and expressed as percentage of a standard serum At. . +++ patzents was found to be 5L~.7 (n=L~); slgnlflcance was set at p<O.O5 using the Wilcoxon slgned rank test 9 Connlesion: These results lndicate that the demonstrated phenomena of a decreased CA in colorectal cancer patients which was more pronounced in the tumor draining than in the perlpheral blood could be related to a complement consumption in tumor patients, especially in the tumor reglon. fhls effects may be due to an increased complement activation by tumor antigens. While the overall correlation of the kits was quite good, (r = 0,73 0,89), the slopes of the correlation curves varied remarkably (0,7 -2,1). The comparison of individual results however was alarming: A pooled serum for quality control differed over 100% (19,0 42,5) . A I:I dilution of the WHO-standard 2/22 J corresponding to 20 ng CEA/ml showed variations over 500% (5, 9 30,2). Depending on the "accidental" sequence of the used kits, patients showed remission (46-39-31-25-24-23-21-21-20-19-18-7) or bad progress (4-5-6-7-7-9-10-11-11-17-19-23) or intermitting course of tumor disease (17-14-10-11-15-18-12-11-3-11-16-20 
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PLASMA MELATONIN IN PATIENTS WITH GASTROINTESTINAL CARCI NOMA
gStemme . R khoorv ~kalickv and W.Schloot The pineal gland is a neuroendocrine transducer which ie involved in the process of biological rhythms of the organimm, The link between the pineal gland or its specific hormone melatonin and malignancy is dicussed since morphological change in this gland in autopsied cases bearing neopIaeies were made (N, Lapinl Pineal Gland and Malignancy,Z,Onkol, 3, 51-60, 1976 Left, S, 377-386, 1983) , We ihue examined mmlatonin levels in patients suffering from gastrointestinal carcinoma, Blood samples were collected between II,30 and 12,30 hours (daytime) and between 23,30 and 0,30 hours (nighttime) from 34 patients hompitalized for non-malignant diseasee and from 12 patiente with diagnoeie of gamtrointsmtinal carcinoma, A iodinated melatonin RIA has been used for the determination of plasma melatonin concentrations, In controls we observed great interindividuaI variability in melatonin levels during daytime, Mean value for this sample was 40 pg/ml ~ 7 8EM, Mean daytime value for patients with gastrointestinal carcinoma was gG pg/ml • B SEW, Nighttime values were even more variable in both groups, Mean value for controls during nighttime was 94 pg/m] • 24 SEW, Nighttime value of gastrointestinal carcinoma was 42 pg/ml • 6 SEM, There wam no statistical mignificance between daytime or nighttime melatonin levels in patients with gastrointestinal carcinoma and controls, The ratio night/day melatonin level in controls was 2,9; in patients with gastrointestinal carcinoma 1,6, This difference was statistically significant on p < O,OS (student-t-test), Thus, the absence of nocturnal peak meletonin (indicated by decreased ratio of night/day-melatonin plasma level) aay serve as a biochemical marker for increased risk of developing gastrointestinal cancer ae discussed by others for breast cancer (see L, Tarmarkin), But because of the high interindividuel variability in plasma meletonin levels in patientm with gastrointestinal carcinoma and in controls further investigations about this phenomenon are necsssar~Chirurg. Klinik, ZKH Links der Weser,2800 Bremen
